{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:48:06Z","timestamp":1790765286265,"version":"4.1.0"},"reference-count":159,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The hormones amylin and calcitonin interact with receptors within the same family to exert their effects on the human organism. Calcitonin, derived from thyroid C cells, is known for its inhibitory effect on osteoclasts. Calcitonin of mammalian origin promotes insulin sensitivity, while the more potent calcitonin extracted from salmon additionally inhibits gastric emptying, promotes gallbladder relaxation, increases energy expenditure and induces satiety as well as weight loss. Amylin, derived from pancreatic beta cells, regulates plasma glucose by delaying gastric emptying after meal ingestion, and modulates glucagon secretion and central satiety signals in the brain. Thus, both hormones seem to have metabolic effects of relevance in the context of non-alcoholic fatty liver disease (NAFLD) and other metabolic diseases. In rats, studies with dual amylin and calcitonin receptor agonists have demonstrated robust body weight loss, improved glucose tolerance and a decreased deposition of fat in liver tissue beyond what is observed after a body weight loss. The translational aspects of these preclinical data currently remain unknown. Here, we describe the physiology, pathophysiology, and pharmacological effects of amylin and calcitonin and review preclinical and clinical findings alluding to the future potential of amylin and calcitonin-based drugs for the treatment of obesity and NAFLD.<\/jats:p>","DOI":"10.3389\/fendo.2020.617400","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T23:17:43Z","timestamp":1610061463000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat"],"prefix":"10.3389","volume":"11","author":[{"given":"David S.","family":"Mathiesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asger","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatan I.","family":"Bagger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i30.3361","article-title":"Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis","volume":"24","author":"Leoni","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1210\/endrev\/bnz009","article-title":"Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management","volume":"41","author":"Marjot","year":"2020","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106021","article-title":"Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis","volume":"56","author":"Assy","year":"2007","journal-title":"Gut"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00121.2014","article-title":"A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats","volume":"307","author":"Andreassen","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00514.2015","article-title":"KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight","volume":"310","author":"Gydesen","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.05.051","article-title":"KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration","volume":"762","author":"Hjuler","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21563","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity","volume":"24","author":"Hjuler","year":"2016","journal-title":"Obesity"},{"key":"B13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/jpet.119.263723","article-title":"The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action","volume":"373","author":"Sonne","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000666","article-title":"The Association between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in United States Population","volume":"51","author":"Jinjuvadia","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e8179","DOI":"10.1097\/MD.0000000000008179","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"96","author":"Dai","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.3.603","article-title":"Reversal of Nonalcoholic Hepatic Steatosis, Hepatic Insulin Resistance, and Hyperglycemia by Moderate Weight Reduction in Patients With Type 2 Diabetes","volume":"54","author":"Petersen","year":"2005","journal-title":"Diabetes"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/db19-0715","article-title":"Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis","volume":"69","author":"Suppli","year":"2020","journal-title":"Diabetes"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198106183042504","article-title":"Glucagon and the a Cell","volume":"304","author":"Unger","year":"1981","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92814-v","article-title":"Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study","volume":"340","author":"Martin","year":"1992","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2174\/138161210791208875","article-title":"Insulin resistance in nonalcoholic fatty liver disease","volume":"16","author":"Bugianesi","year":"2010","journal-title":"Curr Pharm Des"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-8","article-title":"Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes","volume":"11","author":"Neff","year":"2013","journal-title":"BMC Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: Pharmacology, Physiology, and Clinical Potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00419.2016","article-title":"Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog","volume":"313","author":"Gydesen","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/BF00404025","article-title":"Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans","volume":"34","author":"Hartter","year":"1991","journal-title":"Diabetologia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/diab.39.6.752","article-title":"Effects of Meal Ingestion on Plasma Amylin Concentration in NIDDM and Nondiabetic Humans","volume":"39","author":"Butler","year":"1990","journal-title":"Diabetes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2010.03.001","article-title":"Brainstem mechanisms of amylin-induced anorexia","volume":"100","author":"Potes","year":"2010","journal-title":"Physiol Behav"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.11.009","article-title":"Amylin \u2013 Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity","volume":"8","author":"Boyle","year":"2017","journal-title":"Mol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0026-0495(96)90192-4","article-title":"Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake","volume":"45","author":"Young","year":"1996","journal-title":"Metab Clin Exp"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050646","article-title":"Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM","volume":"40","author":"Kong","year":"1997","journal-title":"Diabetologia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00190.2017","article-title":"Relationship of gastric emptying or accommodation with satiation, satiety, and postprandial symptoms in health","volume":"313","author":"Halawi","year":"2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0026-0495(97)90170-0","article-title":"Dose-response for glucagonostatic effect of amylin in rats","volume":"46","author":"Gedulin","year":"1997","journal-title":"Metab Clin Exp"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2001.280.3.E443","article-title":"Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas","volume":"280","author":"Silvestre","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/30666","article-title":"RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor","volume":"393","author":"McLatchie","year":"1998","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e92042","DOI":"10.1371\/journal.pone.0092042","article-title":"Prolonged Calcitonin Receptor Signaling by Salmon, but Not Human Calcitonin, Reveals Ligand Bias","volume":"9","author":"Andreassen","year":"2014","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1124\/mol.56.1.235","article-title":"Multiple Amylin Receptors Arise from Receptor Activity-Modifying Protein Interaction with the Calcitonin Receptor Gene Product","volume":"56","author":"Christopoulos","year":"1999","journal-title":"Mol Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2006.04.001","article-title":"Amylinergic control of food intake","volume":"89","author":"Lutz","year":"2006","journal-title":"Physiol Behav"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2337\/db19-0849","article-title":"Amylin\/Calcitonin Receptor-Mediated Signaling in POMC Neurons Influences Energy Balance and Locomotor Activity in Chow-Fed Male Mice","volume":"69","author":"Coester","year":"2020","journal-title":"Diabetes"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.008615","article-title":"Pharmacological Discrimination of Calcitonin Receptor: Receptor Activity-Modifying Protein Complexes","volume":"67","author":"Hay","year":"2005","journal-title":"Mol Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1658","article-title":"Activity of Pramlintide, Rat and Human Amylin but not A\u03b21\u201342 at Human Amylin Receptors","volume":"155","author":"Gingell","year":"2014","journal-title":"Endocrinology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M","article-title":"Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin","volume":"37","author":"Young","year":"1996","journal-title":"Drug Dev Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(95)02067-5","article-title":"Amylin decreases meal size in rats","volume":"58","author":"Lutz","year":"1995","journal-title":"Physiol Behav"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1996.271.6.R1654","article-title":"Chronic infusion of islet amyloid polypeptide causes anorexia in rats","volume":"271","author":"Arnelo","year":"1996","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2004.01.006","article-title":"Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats","volume":"81","author":"Mollet","year":"2004","journal-title":"Physiol Behav"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00213.2004","article-title":"Amylin receptor blockade stimulates food intake in rats","volume":"287","author":"Reidelberger","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.physbeh.2010.04.012","article-title":"CENTRAL AMYLIN ACTS AS AN ADIPOSITY SIGNAL TO CONTROL BODY WEIGHT AND ENERGY EXPENDITURE","volume":"101","author":"WIELINGA","year":"2010","journal-title":"Physiol Behav"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.1210\/endo.142.11.8593","article-title":"Inhibition of central amylin signaling increases food intake and body adiposity in rats","volume":"142","author":"Rushing","year":"2001","journal-title":"Endocrinology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0393","article-title":"Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression","volume":"147","author":"Roth","year":"2006","journal-title":"Endocrinology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00297.2007","article-title":"Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight","volume":"293","author":"Mack","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s0031-9384(98)00110-3","article-title":"Synergy between amylin and cholecystokinin for inhibition of food intake in mice","volume":"64","author":"Bhavsar","year":"1998","journal-title":"Physiol Behav"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/s0196-9781(02)00280-2","article-title":"Endogenous amylin contributes to the anorectic effects of cholecystokinin and bombesin","volume":"24","author":"Mollet","year":"2003","journal-title":"Peptides"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(95)02046-2","article-title":"Attenuation of the anorectic effects of glucagon, cholecystokinin, and bombesin by the amylin receptor antagonist CGRP(8-37)","volume":"17","author":"Lutz","year":"1996","journal-title":"Peptides"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/s0031-9384(00)00302-4","article-title":"Attenuation of the anorectic effects of cholecystokinin and bombesin by the specific amylin antagonist AC 253","volume":"70","author":"Lutz","year":"2000","journal-title":"Physiol Behav"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1984.246.5.R776","article-title":"Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats","volume":"246","author":"West","year":"1984","journal-title":"Am J Physiol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2002.018671","article-title":"Salmon calcitonin - a potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents","volume":"541","author":"Eiden","year":"2002","journal-title":"J Physiol (Lond)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2007.03.017","article-title":"Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin","volume":"91","author":"Osto","year":"2007","journal-title":"Physiol Behav"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706473105","article-title":"Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies","volume":"105","author":"Roth","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2011.04.044","article-title":"Influence of high-fat feeding, diet-induced obesity, and hyperamylinemia on the sensitivity to acute amylin","volume":"104","author":"Boyle","year":"2011","journal-title":"Physiol Behav"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(86)90708-4","article-title":"A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas","volume":"140","author":"Westermark","year":"1986","journal-title":"Biochem Biophys Res Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.74.5.1569151","article-title":"Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man","volume":"74","author":"Bretherton-Watt","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/BF00401050","article-title":"Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man","volume":"33","author":"Bretherton-Watt","year":"1990","journal-title":"Diabetologia"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2337\/diab.40.12.1615","article-title":"Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes","volume":"40","author":"Ludvik","year":"1991","journal-title":"Diabetes"},{"key":"B66","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0168-8227(92)90074-2","article-title":"Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus","volume":"15","author":"Enoki","year":"1992","journal-title":"Diabetes Res Clin Pract"},{"key":"B67","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0168-8227(92)90073-Z","article-title":"Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus","volume":"15","author":"Hanabusa","year":"1992","journal-title":"Diabetes Res Clin Pract"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.78.5.8175987","article-title":"Amylin\/insulin secretory ratios in morbidly obese man: inverse relationship with glucose disappearance rate","volume":"78","author":"Blackard","year":"1994","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"B69","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s001250050092","article-title":"Role of islet amyloid polypeptide secretion in insulin-resistant humans","volume":"37","author":"Kautzky-Willer","year":"1994","journal-title":"Diabetologia"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1515\/jpem.2010.204","article-title":"Changes in Dynamic Insulin and Gastrointestinal Hormone Secretion in Obese Children","volume":"23","author":"Roth","year":"2010","journal-title":"J\u00a0Pediatr Endocrinol Metab"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2011.52.2.257","article-title":"Delayed Response of Amylin Levels after an Oral Glucose Challenge in Children with Prader-Willi Syndrome","volume":"52","author":"Lee","year":"2011","journal-title":"Yonsei Med J"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-012-0621-4","article-title":"Changes in Gastrointestinal Hormone Responses, Insulin Sensitivity, and Beta-Cell Function Within 2 Weeks After Gastric Bypass in Non-diabetic Subjects","volume":"22","author":"Jacobsen","year":"2012","journal-title":"OBES Surg"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20805","article-title":"Effect of a test meal on meal responses of satiation hormones and their association to insulin resistance in obese adolescents","volume":"22","author":"Beglinger","year":"2014","journal-title":"Obesity"},{"key":"B74","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/nu11010157","article-title":"A Plant-Based Meal Increases Gastrointestinal Hormones and Satiety More Than an Energy- and Macronutrient-Matched Processed-Meat Meal in T2D, Obese, and Healthy Men: A Three-Group Randomized Crossover Study","volume":"11","author":"Klementova","year":"2019","journal-title":"Nutrients"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00131.2013","article-title":"Effects of an intensive short-term diet and exercise intervention: comparison between normal-weight and obese children","volume":"305","author":"Roberts","year":"2013","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1994.267.1.E156","article-title":"Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity","volume":"267","author":"Pieber","year":"1994","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2011.02.015","article-title":"Amylinergic control of food intake in lean and obese rodents","volume":"105","author":"Boyle","year":"2011","journal-title":"Physiol Behav"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1159\/000180515","article-title":"Kidney and calcitonin","volume":"15","author":"Ardaillou","year":"1975","journal-title":"Nephron"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1869","article-title":"Calcitonin: Physiology or fantasy","volume":"28","author":"Davey","year":"2013","journal-title":"J Bone Mineral Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109636","article-title":"Regulation of Calcitonin Secretion in Normal Man by Changes of Serum Calcium within the Physiologic Range","volume":"64","author":"Austin","year":"1979","journal-title":"J Clin Invest"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1210\/endo-70-5-638","article-title":"Evidence for calcitonin\u2013a new hormone from the parathyroid that lowers blood calcium","volume":"70","author":"Copp","year":"1962","journal-title":"Endocrinology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198708273170904","article-title":"Axial and Appendicular Bone Mineral Density in Patients with Long-Term Deficiency or Excess of Calcitonin","volume":"317","author":"Hurley","year":"1987","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.5.6606","article-title":"Comparison of Alendronate and Intranasal Calcitonin for Treatment of Osteoporosis in Postmenopausal Women","volume":"85","author":"Downs","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(99)00208-9","article-title":"Amylin receptors mediate the anorectic action of salmon calcitonin (sCT)","volume":"21","author":"Lutz","year":"2000","journal-title":"Peptides"},{"key":"B85","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/BF02581349","article-title":"Effect of human calcitonin (hCT) on glucose- and arginine-stimulated insulin secretion","volume":"23","author":"Sgambato","year":"1986","journal-title":"Acta Diabetes lat"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1982.242.3.E206","article-title":"Calcitonin modulation of insulin and glucagon secretion in man","volume":"242","author":"Giugliano","year":"1982","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B87","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1055\/s-0028-1097084","article-title":"Effects of hypercalcemia, hypercalcemia and calcitonin on glucose stimulated insulin secretion in man","volume":"4","author":"Ziegler","year":"1972","journal-title":"Horm Metab Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.14310\/horm.2002.1322","article-title":"Hyperinsulinemia during oral glucose tolerance test and high normal serum cortisol are associated with increased secretion of calcitonin in normal subjects","volume":"10","author":"Polymeris","year":"2011","journal-title":"HORMONES"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-978866","article-title":"Stimulatory Effect of Insulin on Calcitonin Secretion","volume":"30","author":"Care","year":"1998","journal-title":"Horm Metab Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj1954.38.343","article-title":"Relation between Body Size and Bone Mineral Density with special reference to Sex Hormones and Calcium Regulating Hormones in Elderly Females","volume":"38","author":"Shiraki","year":"1991","journal-title":"Endocrinol Japonica"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0305","article-title":"Plasma Procalcitonin Is Associated with Obesity, Insulin Resistance, and the Metabolic Syndrome","volume":"95","author":"Abbasi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S3225","article-title":"Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes","volume":"2","author":"Ryan","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"B93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/j.1552-4604.1996.tb04147.x","article-title":"Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro-Amylin, Human) After Intravenous Bolus and Infusion Doses in Patients with Insulin-Dependent Diabetes","volume":"36","author":"Colburn","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00217.2007","article-title":"Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study","volume":"293","author":"Smith","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0029","article-title":"Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-3-201008030-00005","article-title":"Weight and Metabolic Outcomes After 2 Years on a Low-Carbohydrate Versus Low-Fat Diet","volume":"153","author":"Foster","year":"2010","journal-title":"Ann Internal Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2004.76","article-title":"Effect of Pramlintide on Weight in Overweight and Obese Insulin-Treated Type 2 Diabetes Patients","volume":"12","author":"Hollander","year":"2004","journal-title":"Obes Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2006.0013","article-title":"Pramlintide as An Adjunct to Insulin in Patients with Type 2 Diabetes in A Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, And Weight","volume":"9","author":"Karl","year":"2007","journal-title":"Diabetes Technol Ther"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2003.06.003","article-title":"Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis","volume":"52","author":"Maggs","year":"2003","journal-title":"Metabolism"},{"key":"B102","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight Control in Insulin-Treated Subjects with Type 2 Diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0589","article-title":"Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.6.987","article-title":"Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group","volume":"21","author":"Thompson","year":"1998","journal-title":"Diabetes Care"},{"key":"B105","article-title":"Effects Of Six Months Administration Of Pramlintide As An Adjunct To Insulin Therapy On Metabolic Control In People With Type 1 Diabetes","volume":"48","author":"Fineman","year":"1999","journal-title":"Diabetes"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabetic Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4158\/EP09044.ORR1","article-title":"Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study","volume":"15","author":"Huffman","year":"2009","journal-title":"Endocr Pract"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.4158\/EP.15.3.229","article-title":"Minimal Reduction in Insulin Dosage with Pramlintide Therapy when Pretreatment Near-Normal Glycemia is Established and Square-Wave Meal Bolus is Used","volume":"15","author":"King","year":"2009","journal-title":"Endocrine Pract"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3750","article-title":"Chase HP. A Pilot Trial of Pramlintide Home Usage in Adolescents With Type 1 Diabetes","volume":"124","author":"Kishiyama","year":"2009","journal-title":"Pediatrics"},{"key":"B110","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1055\/s-2005-837662","article-title":"Adjunctive Therapy with Pramlintide Lowers HbA1c without Concomitant Weight Gain and Increased Risk of Severe Hypoglycemia in Patients with Type 1 Diabetes Approaching Glycemic Targets","volume":"113","author":"Ratner","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0089","article-title":"Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide","volume":"39","author":"Sherr","year":"2016","journal-title":"Diabetes Care"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.4.724","article-title":"Kolterman OG. A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.039453","article-title":"Lifestyle Modification for Obesity","volume":"125","author":"Wadden Thomas","year":"2012","journal-title":"Circulation"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Bray","year":"2009","journal-title":"Lancet"},{"key":"B115","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"New Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.20313","article-title":"Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial","volume":"319","author":"Salminen","year":"2018","journal-title":"JAMA"},{"key":"B117","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2016.06.021","article-title":"Unimolecular Polypharmacy for Treatment of Diabetes and Obesity","volume":"24","author":"Tsch\u00f6p","year":"2016","journal-title":"Cell Metab"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-0898","article-title":"Combination Therapy with Amylin and Peptide YY[3\u201336] in Obese Rodents: Anorexigenic Synergy and Weight Loss Additivity","volume":"148","author":"Roth","year":"2007","journal-title":"Endocrinology"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01570.x","article-title":"Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents","volume":"14","author":"Roth","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.478","article-title":"Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial","volume":"18","author":"Aronne","year":"2010","journal-title":"Obesity"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced Weight Loss With Pramlintide\/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obes (Silver Spring)"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00275.2010","article-title":"Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates","volume":"299","author":"Bello","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-44591-8","article-title":"Combined Amylin\/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss","volume":"9","author":"Liberini","year":"2019","journal-title":"Sci Rep"},{"key":"B124","unstructured":"Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity2020"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2009.238","article-title":"Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight","volume":"34","author":"Mack","year":"2010","journal-title":"Int J Obes"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01465.x","article-title":"Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide","volume":"13","author":"Mack","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1660213","article-title":"Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors","volume":"166","author":"Hilton","year":"2000","journal-title":"J Endocrinol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13427","article-title":"Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases","volume":"127","author":"Zakariassen","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-013-9987-4","article-title":"Preparation and characterization of PEGylated amylin","volume":"14","author":"Guerreiro","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.2174\/09298665113209990067","article-title":"Amylin conjugation with methoxyl polyethyleneglycol","volume":"20","author":"Guterres","year":"2013","journal-title":"Protein Pept Lett"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1039\/c4ob01208a","article-title":"Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure-activity relationships for amylin receptor agonism","volume":"12","author":"Kowalczyk","year":"2014","journal-title":"Org Biomol Chem"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.04.004","article-title":"BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats","volume":"114","author":"Nascimento","year":"2019","journal-title":"Peptides"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/chem.201303303","article-title":"Glycosylation of pramlintide: synthetic glycopeptides that display in vitro and in vivo activities as amylin receptor agonists","volume":"19","author":"Tomabechi","year":"2013","journal-title":"Chemistry"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1039\/c6ob00850j","article-title":"Synthesis and amylin receptor activity of glycomimetics of pramlintide using click chemistry","volume":"14","author":"Yule","year":"2016","journal-title":"Org Biomol Chem"},{"key":"B135","unstructured":"Human amylin analogues\n            DahlK\n            SCH\u00c4FFERL\n            KruseT\n          2013"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9557-6","article-title":"Modeling energy intake and body weight effects of a long-acting amylin analogue","volume":"45","author":"Brings","year":"2018","journal-title":"J Pharmacokinet Pharmacodynamics"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e12910","DOI":"10.1111\/adb.12910","article-title":"Effects of a selective long-acting amylin receptor agonist on alcohol consumption, food intake and body weight in male and female rats","author":"Kalafateli","year":"2020","journal-title":"Addict Biol"},{"key":"B138","unstructured":"Investigation of Pharmacokinetic Properties, Safety and Tolerability of Single Subcutaneous Doses of NNC0174-0833 in Male Japanese and Caucasian Subjects Being Normal Weight, Overweight or With Obesity2019"},{"key":"B139","unstructured":"Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial2020"},{"key":"B140","unstructured":"Efficacy and Safety of AM833 for Weight Loss: A Dose-finding Trial in Adults With Overweight\/Obesity. Oral 043\n            LauDCW\n            McFarlaneJ\n            ErichsenL\n            FransiscoAM\n            Le RouxC\n            McGowanB"},{"key":"B141","unstructured":"Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity2020"},{"key":"B142","article-title":"Anti-diabetic effects of novel long-acting amylin analogues ZP4982 and ZP5461 in ZDF rats.1","author":"Skarbaliene","year":""},{"key":"B143","article-title":"Anti-obesity effects of the novel long-acting amylin analogue ZP4982 in high-fat diet fed rats.1","author":"Skarbaliene","year":""},{"key":"B144","unstructured":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 473494 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)2018"},{"key":"B145","unstructured":"Zealand Pharma regains worldwide rights to Amylin analog program from Boehringer Ingelheim2020"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1042\/cs040009Pb","article-title":"Comparison of Human, Porcine and Salmon Synthetic Calcitonins in Man and the Rat","volume":"40","author":"Galante","year":"1971","journal-title":"Clin Sci"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1136\/gut.30.4.430","article-title":"Effect of calcitonin on gastric emptying and on postprandial gastrin and insulin release in patients with type I gastric ulcer","volume":"37","author":"Jonderko","year":"1990","journal-title":"Neth J Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1989.tb00854.x","article-title":"Effect of calcitonin on gall-bladder volume in man","volume":"4","author":"Jonderko","year":"1989","journal-title":"J Gastroenterol Hepatol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0196-9781(82)90135-8","article-title":"The effect of calcitonin on food intake in diabetic mice","volume":"3","author":"Morley","year":"1982","journal-title":"Peptides"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(80)90196-3","article-title":"Calcitonin reduces feeding in man, monkey and rat","volume":"12","author":"Perlow","year":"1980","journal-title":"Pharmacol Biochem Behav"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01425.x","article-title":"A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats","volume":"13","author":"Feigh","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.05.016","article-title":"Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats","volume":"737","author":"Feigh","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2007.02.012","article-title":"The acute effect of amylin and salmon calcitonin on energy expenditure","volume":"91","author":"Wielinga","year":"2007","journal-title":"Physiol Behav"},{"key":"B154","first-page":"61","article-title":"Amylin Receptor Phenotypes Derived from Human Calcitonin Receptor\/RAMP Coexpression Exhibit Pharmacological Differences Dependent on Receptor Isoform and Host Cell Environment","volume":"294","author":"Tilakaratne","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"B155","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1124\/jpet.119.263392","article-title":"The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy","volume":"374","author":"Larsen","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"B156","unstructured":"Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes - Full Text View - ClinicalTrials.gov"},{"key":"B157","unstructured":"Lilly cuts a trio of pipeline assets, including BTK inhibitor, diabetes drug"},{"key":"B158","unstructured":"Danish biotech boss after shelved Lilly project: \u201cWe have better molecules"},{"key":"B159","unstructured":"A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM - Full Text View - ClinicalTrials.gov"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.617400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T23:17:58Z","timestamp":1610061478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.617400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":159,"alternative-id":["10.3389\/fendo.2020.617400"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.617400","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"article-number":"617400"}}